Chondroprotectives and their effect on the cartilage properties

Česká verzia

Authors: J. Rychlíčková
Authors place of work: Farmakologický ústav LF, Kamenice, Brno ; Oddělení klinické farmacie, Ústavní lékárna, Masarykův onkologický ústav, Brno
Published in the journal: Geriatrie a Gerontologie 2018, 7, č. 4: 167-169
Category: Review Article

Summary

The current therapy of osteoarthritis is based on symptomatic pain management and possible use of chondroprotectives. The ideal chondroprotective agent is able to slow down the progressive narrowing of the joint space, to give protection to chondrocytes and to improve biomechanical properties of the cartilage. There are many different agents available, with declared positive influence on the cartilage function. We will focus on two of them, glucosamine and chondroitin, which the most marketed products are based on. The basic pharmacology properties, quality limits of clinical trials and aspects of rational use of these drugs in clinical practice will be discussed.

Keywords:

chondroprotectives – glucosamine sulphate – chondroitin sulphate – osteoarthritis treatment

Zdroje

1. Fox AJS, Bedi A, Rodeo SA. The basic science of articular cartilage. Structure, composition, and function. Sports Health 2009; 1(6): 461–468.

2. Vasiliadis HS, Tsikopoulos K. Glucosamine and chondroitin for the treatment of osteoarthritis. World Journal of Orthopedics 2017; 8(1): 1–11.

3. Pavelka K. Konzervativní léčba osteoartrózy váhonosných kloubů. Postgraduální medicína 2001; 2. cit. 10-10-2018.

4. Brandt KD. Diagnosis and Nonsurgical Management of Osteoarthritis [online].5th ed. Professional Communications, 2010 [cit. 2018-10-13].

5. deCampos, GC. Chondroprotective agents: are we being too dogmatic? Medical Express. 2014; 1(4): 211–213.

6. Aghazadeh-Habashi A, Jamali F. The glukosamine controversy; a pharmacokinetic issue. Journal of Pharmacy&Phamaceutical Sciences. 2011; 14(2): 264–273.

7. Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacology&Therapeutics. 2014; 142(3): 362–374.

8. Uldry M, Ibberson M, Hosokawa M, et al. GLUT2 is a high affinity glucosamine transporter. FEBS Letters 2002; 524(1–3): 199–203.

9. Setnikar I. Antireactive properties of “chondroprotective“ drugs. International Journal of Tissue Reactions 1992; 14(5): 253–261.

10. Reginster JY, Neuprez A, Lecart MP, et al. Role of glucosamine in treatment for osteoarthritis. Rheumatology International 2012; 32(10): 2959–2967.

11. Cutolo M, Berenbaum F, Hochberg M, et al. Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in Arthritis and Rheumatism 2015; 44(6): 611–617.

12. Treatment of osteoarthritis of the knee. Evidence-based guideline 2nd edition. American Academy of Orthopaedic Surgeons. 2013. [cit. 10-10-2018]. Dostupné z: www.aaos.org.

13. Management of osteoarthritis of the hip: evidence-based clinical practice guideline. American Academy of Orthopaedic Surgeons. 2017. [cit. 10-10-2018]. Dostupné z: www.orthoguidelines.org.

14. Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism. 2014; 44(3): 253–263.